ClinicalTrials.gg
CompletedNCT00315744Updated Oct 19, 2017

Viapaed Study In Children And Adolescents With Asthma

A Phase 4 interventional study of Salmeterol/fluticasone and Fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Completed at 98 sites in Germany. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2017-10-19.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Nov 2004, registered Apr 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
4 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 46 studies testing Salmeterol Xinafoate in Asthma — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Asthma.

Enrollment
17th of 46
285 · median 128
Started
2004
with 6 others
Phase 4
26 of 46
none open now
Registered
13th of 46
by date
Lead sponsor
22 of 46
GlaxoSmithKline

Among the 46 studies testing Salmeterol Xinafoate in Asthma, this one is the 17th largest by enrollment, is one of 7 that started in 2004, is one of 26 in phase 4, and was the 13th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 46 studies testing Salmeterol Xinafoate in Asthma is open now. The open studies under Asthma, anywhere →

About Salmeterol Xinafoate

Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies testing Salmeterol Xinafoate in Asthma as a file.
02

Study summary

Asthmatic children who remain symptomatic on inhaled corticosteroids (ICS) require an adjustment of their asthma therapy. Current guidelines suggest that the treatment options are either an increased dose of inhaled corticosteroid or the addition of other therapy such as a long-acting beta-agonist (LABA). In the pediatric age range, major concerns with respect to high dose ICS therapy are growth retardation and the suppression of the hypothalamic-pituitary-adrenocortical (HPA) axis. Previous studies in adults have shown that a combination product that included a LABA as well as the ICS allowed to reduce the steroid dose and was still at least as effective in achieving asthma control as treatment with a higher dose of ICS. These treatment options shall be compared in the present study. Children who remain symptomatic while inhaling 100 µg fluticasone (FP) twice daily shall be randomized to receive the salmeterol/ fluticasone combination product, Viani (SERETIDE) 50/100 µg, or fluticasone 200 µg as a comparator drug, inhaled twice daily via the DISKUS for a period of eight weeks.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • moderate asthma
  • fluticasone
  • children
  • salmeterol
  • steroid-sparing
  • Asthma
04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Children aged 4 to 16 years with an established history of perennial asthma.
  • Subjects who are treated with an inhaled according to BDP (budesonide) 200-400 µg/day or equivalent during the last 4 weeks before run-in.
  • 15 minutes after inhaling 200µg of salbutamol, reversible increase in of at least 12% of the pre-dose value.
  • Willingness to substitute previous controller medication on the twice daily inhalation of fluticasone 100µg bid via DISKUS®.
  • Subjects/guardians who have given written to participate in the study.
  • Subjects /guardians who are able to understand and complete a diary record card (DRC).
  • Subjects who are able to use a Mini-Wright Peak Flow meter.
  • Sexually active female adolescents must use adequate .
  • Willingness to refrain from any other controller medication (including anti-leukotrienes) or from regular use of short-acting beta agonists or anticholinergics during the treatment period.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Enrollment
285 participants (actual)

Study arms

  • Experimental
    Subjects receiving salmeterol/fluticasone

    Eligible subjects will receive 60 individual doses of the salmeterol 50 microgram/ fluticasone 100 microgram combination. Subjects will also receive placebo.

    Drug: Salmeterol/fluticasone · Drug: Salbutamol

  • Active comparator
    Subjects receiving fluticasone

    Eligible subjects will receive 60 individual fluticasone 100 microgram doses each.

    Drug: Fluticasone propionate · Drug: Salbutamol

Interventions

  • DrugSalmeterol/fluticasone

    Drug pages: Salmeterol Xinafoate · Fluticasone

    Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.

  • Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.

    Also known as: Salmeterol, SERETIDE

  • Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in mean morning peak expiratory flow (PEF)

    The PEF is a person's maximum speed of expiration. PEF will be measured using a mini wright peak flow meter and will be documented daily at morning in the diary of subjects

    Time frame: Baseline up to Week 8

Secondary outcomes

  1. Daily Asthma symptom score

    Asthma symptoms will be recorded separately for night and day using 2 symptom scores. Symptoms included will be coughing, wheezing, shortness of breath, feeling of tightness in the chest and nocturnal waking due to 1 or more of these symptoms. Score will range from 0-4 where 0 = no complaints and 4= person could not sleep due to asthma symptoms.

    Time frame: Up to Week 8

  2. Number of calendar days without asthma symptoms

    Number of calendar days without asthma symptoms will be defined as the sum of all days for which the patient documented an asthma symptom score of 0 (no complaints) for the day and the previous night.

    Time frame: Up to Week 8

  3. Number of necessary administrations of salbutamol

    The number of necessary administrations of salbutamol will be documented daily by subjects in the diary.

    Time frame: Up to Week 8

  4. Number of weeks with good asthma control

    One week of well controlled asthma will be defined by fulfilling the following criteria: at least 2 of the following criteria (type A): symptoms with a symptom score \>1 on at most 2 days, use of rescue medication maximally 4 x per week, morning PEF daily \>=80% of the predicted normal value and all the following criteria (type B): no nocturnal waking due to bronchial asthma, no exacerbations, no out-patient or hospitalized emergency treatment due to asthma, no adverse events due to administration of the study medication which would have necessitated a change of treatment, no intolerance or refusal of study medication

    Time frame: Up to Week 8

  5. Change in forced vital capacity (FVC) in % of reference value

    FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deep breath.

    Time frame: Up to Week 8

  6. Change in forced expiratory volume in 1 second (FEV1) in % of reference value

    FEV1 is the volume of air exhaled under forced conditions in 1 second.

    Time frame: Up to Week 8

  7. Change in peak expiratory flow rate (PEFR) in % of reference value

    PEFR is a person's maximum speed of expiration.

    Time frame: Up to Week 8

  8. Change in mean morning peak flow in % of reference value

    The PEF is a person's maximum speed of expiration. PEF will be measured using a mini wright peak flow meter

    Time frame: Up to Week 8

  9. Percentage of subjects with a peak flow variability of 20%

    Morning versus evening peak flow will be calculated and compared.

    Time frame: Up to Week 8

  10. Number of subject withdrawals due to asthma exacerbations

    Asthma exacerbations are acute or sub acute episodes, which are characterized by a progressive increase in one or more typical asthma symptoms.

    Time frame: Up to Week 8

  11. Number of subjects with adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Up to Week 8

07

Study locations

98 sites
  • GSK Investigational Site
    Bad Krozingen, Baden-Wuerttemberg 79189, Germany
  • GSK Investigational Site
    Boennigheim, Baden-Wuerttemberg 74357, Germany
  • GSK Investigational Site
    Ettenheim, Baden-Wuerttemberg 77955, Germany
  • GSK Investigational Site
    Heidelberg, Baden-Wuerttemberg 69115, Germany
  • GSK Investigational Site
    Kehl, Baden-Wuerttemberg 77694, Germany
  • GSK Investigational Site
    Konstanz, Baden-Wuerttemberg 78464, Germany
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68167, Germany
  • GSK Investigational Site
    Pfullendorf, Baden-Wuerttemberg 88630, Germany
  • GSK Investigational Site
    Schwaebisch-Hall, Baden-Wuerttemberg 74523, Germany
  • GSK Investigational Site
    Schwetzingen, Baden-Wuerttemberg 68723, Germany
  • GSK Investigational Site
    Sinsheim, Baden-Wuerttemberg 74889, Germany
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70469, Germany
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70499, Germany
  • GSK Investigational Site
    Tauberbischofsheim, Baden-Wuerttemberg 97941, Germany
  • GSK Investigational Site
    Tuttlingen, Baden-Wuerttemberg 78532, Germany
  • GSK Investigational Site
    Villingen-Schwenningen, Baden-Wuerttemberg 78056, Germany
  • GSK Investigational Site
    Welzheim, Baden-Wuerttemberg 73642, Germany
  • GSK Investigational Site
    Bobingen, Bayern 86399, Germany
  • GSK Investigational Site
    Forchheim, Bayern 91301, Germany
  • GSK Investigational Site
    Freising, Bayern 85354, Germany
  • GSK Investigational Site
    Kaufbeuren, Bayern 87600, Germany
  • GSK Investigational Site
    Lauf, Bayern 91207, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80337, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80939, Germany
  • GSK Investigational Site
    Muenchen, Bayern 81241, Germany
  • GSK Investigational Site
    Noerdlingen, Bayern 86720, Germany
  • GSK Investigational Site
    Nuernberg, Bayern 90449, Germany
  • GSK Investigational Site
    Nuernberg, Bayern 90473, Germany
  • GSK Investigational Site
    Olching, Bayern 82140, Germany
  • GSK Investigational Site
    Pegnitz, Bayern 91257, Germany
  • GSK Investigational Site
    Rosenheim, Bayern 83026, Germany
  • GSK Investigational Site
    Friedrichsfelde, Berlin 10315, Germany
  • GSK Investigational Site
    Frankfurt/Oder, Brandenburg 15236, Germany
  • GSK Investigational Site
    Schwedt, Brandenburg 16303, Germany
  • GSK Investigational Site
    Braunfels, Hessen 35619, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60316, Germany
  • GSK Investigational Site
    Kassel, Hessen 34121, Germany
  • GSK Investigational Site
    Niedernhausen, Hessen 65527, Germany
  • GSK Investigational Site
    Wetzlar, Hessen 35576, Germany
  • GSK Investigational Site
    Wiesbaden, Hessen 65205, Germany
  • GSK Investigational Site
    Belm, Niedersachsen 49191, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Lueneburg, Niedersachsen 21339, Germany
  • GSK Investigational Site
    Osnabrueck, Niedersachsen 49082, Germany
  • GSK Investigational Site
    Aachen, Nordrhein-Westfalen 52072, Germany
  • GSK Investigational Site
    Bielefeld, Nordrhein-Westfalen 33617, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44789, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44791, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44795, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44866, Germany
  • GSK Investigational Site
    Bottrop, Nordrhein-Westfalen 46242, Germany
  • GSK Investigational Site
    Detmold, Nordrhein-Westfalen 32756, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44137, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40225, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40599, Germany
  • GSK Investigational Site
    Duisburg, Nordrhein-Westfalen 47137, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Euskirchen, Nordrhein-Westfalen 53879, Germany
  • GSK Investigational Site
    Guetersloh, Nordrhein-Westfalen 33332, Germany
  • GSK Investigational Site
    Halle, Nordrhein-Westfalen 33790, Germany
  • GSK Investigational Site
    Kempen, Nordrhein-Westfalen 47906, Germany
  • GSK Investigational Site
    Kleve-Materborn, Nordrhein-Westfalen 47533, Germany
  • GSK Investigational Site
    Krefeld, Nordrhein-Westfalen 47389, Germany
  • GSK Investigational Site
    Minden, Nordrhein-Westfalen 32427, Germany
  • GSK Investigational Site
    Neuss, Nordrhein-Westfalen 41462, Germany
  • GSK Investigational Site
    Neuss, Nordrhein-Westfalen 41469, Germany
  • GSK Investigational Site
    Oberhausen, Nordrhein-Westfalen 46145, Germany
  • GSK Investigational Site
    Remscheid, Nordrhein-Westfalen 42899, Germany
  • GSK Investigational Site
    Wesel, Nordrhein-Westfalen 46483, Germany
  • GSK Investigational Site
    Willich, Nordrhein-Westfalen 47877, Germany
  • GSK Investigational Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55127, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Trier, Rheinland-Pfalz 54294, Germany
  • GSK Investigational Site
    Cossebaude, Sachsen 01462, Germany
  • GSK Investigational Site
    Doebeln, Sachsen 04720, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01067, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01169, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04279, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04317, Germany
  • GSK Investigational Site
    Wurzen, Sachsen 04808, Germany
  • GSK Investigational Site
    Flensburg, Schleswig-Holstein 24944, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Harrislee, Schleswig-Holstein 24955, Germany
  • GSK Investigational Site
    Neuhaus am Rennweg, Thueringen 98724, Germany
  • GSK Investigational Site
    Berlin, 10365, Germany
  • GSK Investigational Site
    Berlin, 10785, Germany
  • GSK Investigational Site
    Berlin, 10965, Germany
  • GSK Investigational Site
    Berlin, 10967, Germany
  • GSK Investigational Site
    Berlin, 10997, Germany
  • GSK Investigational Site
    Berlin, 12161, Germany
  • GSK Investigational Site
    Berlin, 12167, Germany
  • GSK Investigational Site
    Berlin, 13055, Germany
  • GSK Investigational Site
    Berlin, 13347, Germany
  • GSK Investigational Site
    Berlin, 13355, Germany
  • GSK Investigational Site
    Berlin, 14163, Germany
  • GSK Investigational Site
    Hamburg, 22045, Germany
  • GSK Investigational Site
    Hamburg, 22415, Germany
08

References and documents

Publications

  • Gappa M, Zachgo W, von Berg A, Kamin W, Stern-Strater C, Steinkamp G; VIAPAED Study Group. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatr Pulmonol. 2009 Nov;44(11):1132-42. doi: 10.1002/ppul.21120. PubMed 19824054 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2004 to primary completion in Apr 2007, 29 months.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 29 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2006
First posted
Apr 19, 2006
StartActual
Nov 4, 2004
Primary completionActual
Apr 12, 2007
CompletionActual
Apr 12, 2007
Last update
Oct 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00315744
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 19, 2006
Start date
Nov 4, 2004
Primary completion
Apr 12, 2007
Completion
Apr 12, 2007
Last update
Oct 19, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone

Start the discussion